Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB, Fully Enrolled

Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB, Fully Enrolled

292065

Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB, Fully Enrolled

Krystal Biotech announced the full enrollment of a pivotal Phase 3 clinical trial of its topical gene therapy B-VEC (beremagene geperpavec) as a skin wound treatment for people with dystrophic epidermolysis bullosa (DEB). Top-line results on the 31 patients in the randomized GEM-3 trial (NCT04491604), a mix of children and adults, may be available toward year’s end. “Completion of enrollment in the GEM-3 study marks a significant milestone for us,” Suma Krishnan, Krystal’s founder and chief operating office,…

You must be logged in to read/download the full post.